US Wockhardt subsidiary Morton Grove warned by US FDA

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Food and drug administration, Pharmaceutical drug, Us

The US FDA has warned Wockhardt Limited about operations at its US subsidiary Morton Grove Pharmaceuticals Inc. 

Wockhardt announced it had received the letter in a filing on the Bombay Stock Exchange​ (BSE), explaining that as a result the US regulator will not approve any new drugs made at Morton Grove’s facility in North Chicago, US.

The firm said the “current portfolio of the Company will continue to be made available in the market​.”

It also said it had hired consultants to bring the plant up to code, explaining that it has “already initiated appropriate measures since last several months to address the issues raised by US FDA​.”

Wockhardt bought Morton Grove in 2007, citing a desire to add the firm's range of oral liquid and topical pharmaceuticals to its US product range.

The acquisition included a 125,000 square-foot facility that has been operated by Morton Grove has been open since 1995.

The plant has been the subject of US Food and Drug Administration (FDA) already. In 2014​ the US regulatory issued Morton Grove with a Form 483 detailing 12 deviations from current good manufacturing practice (cGMP).

US compliance problems

Wockhardt’s manufacturing network has also been the subject of a number of US FDA warnings.

At present​ Wockhardt’s drug manufacturing plants in Chikhalthana and Waluj in Aurangabad and the active pharmaceutical ingredient (API) unit in Ankleshwar, India are banned from shipping products to the US.

Wockhardt acknowledged the impact the import bans have had on its performance in its financial report for its fiscal third quarter​.

The firm reported sales of INR9.95bn ($149m), down 7.4% on the year-earlier quarter, explaining that “performance during the quarter was affected by subdued business in US market, demonetisation in India and continued remediation costs​.”

Wockhardt did not respond to a request for comment.

The warning letter has not been published by the FDA.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more